December 14, 2023.

Atmo Biosciences has reached its patient recruitment target ahead of schedule for its dysmotility pivotal clinical study.

More than 200 patients were recruited in a multi-site clinical trial to support a submission for initial U.S. regulatory clearance around the use of Atmo’s gas-sensing capsule to assess gastrointestinal motility disorders.

November 16, 2023.

An editorial published in the journal Alimentary Pharmacology and Therapeutics describes Atmo Biosciences’ gas-sensing capsule as disruptive technology that has enabled unlocking of key aspects of microbial metabolism, especially with respect to carbohydrate fermentation.